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Objective: Weight regain after weight loss is common, and there is evi-
dence to suggest negative effects on health because of weight cycling. 
This study sought to investigate the impact of weight regain in formerly 
obese mice on adipose tissue architecture and stromal cell function.
Methods: A diet-switch model was employed for obesity induction, 
weight loss, and weight regain in mice. Flow cytometry quantified 
adipose tissue leukocytes in adipose tissue. Liver and adipose tissue 
depots were compared to determine tissue-specific effects of weight 
cycling.
Results: Epididymal white adipose tissue of formerly obese mice failed 
to expand in response to repeat exposure to high-fat diet and retained 
elevated numbers of macrophages and T cells. Weight regain was associ-
ated with disproportionally elevated liver mass, hepatic triglyceride con-
tent, serum insulin concentration, and serum transaminase concentration. 
These effects occurred despite an extended 6-month weight  loss cycle 
and they demonstrate that formerly obese mice maintain durable altera-
tions in their physiological response to weight regain. Conditioned media 
from epididymal adipose tissue of formerly obese mice inhibited adipo-
genesis of 3T3-L1 preadipocytes, suggesting a potential mechanism to 
explain failed epididymal adipose tissue expansion during weight regain.
Conclusions: Metabolic abnormalities related to defects in adipose tis-
sue expansion and ongoing dysfunction manifest in formerly obese mice 
during weight regain.
Obesity (2020) 28, 1086-1097. 
Introduction
Obesity is associated with increased risk for several comorbidities, including metabolic 
syndrome, type 2 diabetes, and cardiovascular disease. Weight loss, through caloric 
restriction or bariatric surgery, improves metabolic dysfunction and can reduce measures 
of inflammation both systemically and within adipose tissue (1-3). Unfortunately, long-
term maintenance of even 10% weight loss is difficult, and only ~20% of people maintain 
this reduction beyond 1 year (4), regardless of dietary or surgical weight loss (5,6).
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Study Importance
What is already known?
►	Weight cycling may have adverse meta-
bolic consequences.
►	Obesity alters the architecture of adi-
pose tissue.
►	Mechanisms of adverse long-term 
consequences of obesity are not well 
understood.
What does this study add?
►	Formerly obese mice demonstrate dura-
ble changes in epididymal adipose tis-
sue architecture that limit proper depot 
expansion after rechallenge with high-fat 
diet.
►	The failure of adipose tissue to remodel 
and permit healthy expansion continues 
up to 6 months after weight loss in mice 
and exacerbates hepatic steatosis and 
liver dysfunction.
►	Weight cycling sustains CD11c+ adipose 
tissue macrophages, CD8+ adipose tis-
sue T cells, and Col1+ preadipocytes.
How might these results change the 
focus of clinical practice?
►	The results emphasize the importance of 
early obesity treatment and prevention.
►	Long-term consequences of obesity 
even after weight loss can impact meta-
bolic flexibility.
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An open question in the field is whether weight regain and/or weight 
cycling adversely alters metabolic health. Clinical studies have sug-
gested that weight cycling is not associated with increased risk of met-
abolic disease when compared with those with sustained overweight or 
obesity (7-9). However, there are studies showing that weight cycling 
carries a higher risk for diabetes and adverse cardiovascular events 
than non–weight-cycling individuals (10-12). Few studies have evalu-
ated physiological responses or alterations in tissue-specific metabolic 
parameters during the weight regain cycle. Rodent studies have found 
altered fatty acid metabolism with increased lipoprotein lipase, serum 
triglycerides, and serum cholesterol during high-fat diet (HFD) refeed-
ing beyond what is observed in rodents maintained on HFD ad libi-
tum (13-15). Weight cycling was also observed to increase visceral fat 
mass  and inflammatory markers within adipose tissue in association 
with insulin resistance (16-18).
These observations suggest that weight regain in lean individuals who 
used to have obesity may result in unique patterns of dysfunction in met-
abolic tissues, leading to metabolic disease risk. Consistent with this, 
lean adults who used to be children with obesity were shown to retain 
a fivefold higher risk for elevated hemoglobin A1c (19). Inflammatory 
gene expression in adipose tissue of humans who used to have obesity 
remains high compared with lean individuals (20-22). Our group and 
others have demonstrated that weight loss does not resolve adipose tis-
sue inflammation and insulin sensitivity in mice (23-26). Inflammatory 
CD11c+ macrophages and crown-like structures (CLS) are maintained 
within adipose tissue despite extended weight loss associated with per-
sistent impairment in insulin tolerance (23).
We sought to understand the metabolic and inflammatory implications 
of weight cycling using a mouse model of weight gain in formerly obese 
mice. We found that the epididymal white adipose tissue (eWAT) of 
formerly obese mice had impaired expansion and reduced lipid storage 
capacity with HFD refeeding. Weight regain was also associated with 
increased hepatic triglyceride storage and markers of hepatocyte dys-
function. This failure of eWAT expansion occurred despite the presence 
of an expanded preadipocyte pool. Furthermore, eWAT from formerly 
obese mice secreted factors that inhibited adipogenesis in vitro, which 
suggests a mechanism for impaired adipose expansion and persistent 
adipose tissue dysfunction.
Methods
Animals and animal care
At 6 weeks of age, male C57BL/6J mice (Jackson, Bar Harbor, Maine) 
were fed a control normal diet (ND; LabDiet, St. Louis, Missouri; 
PicoLab 5L0D, 4.09 kcal/g, 28.7% calories from protein, 13.4% cal-
ories from fat, 57.9% calories from carbohydrate) or HFD (Research 
Diets, New Brunswick, New Jersey; D12492, 5.21 kcal/g, 20% calories 
from protein, 60% calories from fat, 20% calories from carbohydrate).
Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were per-
formed after 6 hours of fasting. Mice were injected intraperitoneally with 
D-glucose (0.7 g/kg) for GTT and human recombinant insulin (1 U/kg) 
for ITT. Glucose was measured using FreeStyle Lite blood glucose mon-
itors (Abbott, Abbott Park, Illinois). Insulin was measured by enzyme-
linked immunosorbent assay (ELISA; Crystal Chem, Elk Grove Village, 
Illinois). Energy metabolism was measured using Comprehensive Lab 
Animal Monitoring System analysis (CLAMS; Columbus Instruments, 
Columbus, Ohio). All mouse procedures were approved by the University 
of Michigan Committee on Use and Care of Animals and were conducted 
in compliance with the Institute for Laboratory Animal Research Guide 
for the Care and Use of Laboratory Animals.
Gene expression analysis
RNA was extracted from tissues using Trizol LS (Life Technologies, 
Carlsbad, California) and complementary DNA (cDNA) generated using 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Waltham, Massachusetts). SYBR Green PCR Master Mix and the 
StepOnePlus Real-Time PCR System (Applied Biosystems) were used 
for real-time quantitative polymerase chain reaction (PCR) using Gapdh 
expression as an internal control for data normalization. Samples were 
assayed in duplicate, and relative expression was determined using 2−ΔΔ 
CT method (primers in Supporting Information Table S1).
Immunoblotting and immunofluorescence
Adipose tissue was homogenized in radioimmunoprecipitation assay 
lysis buffer with phosphatase inhibitors. Protein concentration was 
determined using Bio-Rad Protein Assay Dye Reagent  (Hercules, 
California). Antibodies used for immunoblotting were as follows: 
PPARγ (81B8), IRS-1, phospho-Akt (Ser473), AKT, adiponectin 
(C45B10) (Cell Signaling Technology, Danvers, Massachusetts), and 
β-actin (AC-40) (Sigma-Aldrich, St. Louis, Missouri). Proteins were 
imaged using Odyssey infrared imaging system (Li-Cor Bioscience, 
Lincoln, Nebraska). Immunofluorescence was performed as previously 
described in adipose tissue explants and fixed overnight in a 2% para-
formaldehyde solution (27). Antibodies used for immunofluorescence 
were caveolin (BD Pharmingen, San Diego, California) and Mac2 
(galectin-3) (eBioM3/38) (eBioscience, San Diego, California).
Isolation of adipose tissue stromal vascular 
fraction and flow cytometry
Adipose tissue was digested in Roswell Park Memorial Institute-1640 
medium (Invitrogen, Carlsbad, California)  with 0.5% bovine serum 
albumin (BSA) and 1 mg/mL of type II collagenase on a rocking plat-
form for 25 minutes at 37°C. The stromal vascular fraction (SVF) was 
separated from adipocytes by centrifugation. The following antibod-
ies were used for flow cytometry following Fc block: CD45 (30-F11), 
CD3e (145-2C11), CD4 (GK1.5), CD8a (53-6.7), CD11c (N418), Sca-1 
(Ly-6A/E) (D7), CD31 (390) (eBioscience), PDGFRα (RM0004-3G28) 
(Abcam, Cambridge, UK), and CD64 (X54-5/7.1) (BD Pharmingen). 
For intracellular collagen staining, cells were incubated in Fc block and 
then stained with surface antibodies for 45 minutes at 4°C. Intracellular 
stains were performed using Forkhead Box P3 Fix/Perm Buffer 
(BioLegend, San Diego, California) followed by a 15-minute block 
with 0.5% goat serum, a 1-hour incubation with 0.5 μg of rabbit colla-
gen type I antibody (Rockland, Limerick, Pennsylvania), three washes, 
and 30-minute incubation with 0.2 μg of goat anti-rabbit Alexa Fluor 
647 antibody (Thermo Fisher Scientific, Carlsbad, California). Analysis 
was performed using a BD FACSCanto II (BD Biosciences, San Jose, 
California) and FlowJo v.10 (Treestar, Ashland, Oregon).
Explant conditioned media
Two hundred milligrams of epididymal adipose tissue explants were 
cultured in serum-free AIM V Medium with AlbuMAX and BSA (Life 
Technologies) to create conditioned media (CM). Confluent 3T3-L1 
cells were treated with a 1:1 mixture of CM and methylisobutylxanthine, 
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dexamethasone, insulin differentiation media (0.5mM methylisobu-
tylxanthine, 1μM dexamethasone, and 10-μg/mL human recombinant 
insulin in DMEM); after 3 days, media was replaced with another 
1:1 mixture of CM and insulin medium (10 μg of insulin in DMEM). 
For tumor necrosis factor alpha (TNFα) neutralizing experiments, CM 
was treated for  1 hour with 100 ng/mL of  blocking antibody before 
using the CM in 3T3-L1 cultures at a final concentration of 50 ng/mL 
(D2H4 mAb; Cell Signaling Technology). For cytokine and chemok-
ine treatments (10 ng/mL; PeproTech, Rocky Hill, New Jersey), 3T3-
L1 cells were treated during both phases of differentiation. Mouse 
Cytokine Antibody Array (R&D Systems,  Minneapolis, Minnesota) 
was used to evaluate adipose tissue explant CM (48 hours, pooled from 
three mice). Quantitation was performed by ImageJ (NIH, Bethesda, 
Maryland) after background subtraction and normalization.
Figure 1 Weight loss and HFD rechallenge model. (A) Diagram of experimental paradigm of obesity induction, weight loss, and HFD rechallenge model and 
longitudinal weight. Body weight after (B) weight loss and (C) HFD rechallenge. (D) Energy expenditure after weight loss and (E) food intake 1 week after starting 
HFD rechallenge phase. (F,G) Glucose tolerance testing  (GTT) at 2 and 4 weeks of HFD rechallenge. (H) Insulin tolerance testing (ITT) after 6 weeks of HFD 
rechallenge. (I) Fasted blood glucose. (J) Fasted serum insulin. For panels A-J, n = 4. *P < 0.05, **P < 0.01, ****P < 0.0001; significance was compared only for ST-
HFD versus RC-HFD, LT-HFD versus RC-HFD, ND versus WL, or WL versus HFD (20 weeks).
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Liver triglyceride quantification
Approximately 100 mg of frozen liver samples was homogenized in 300 μL 
of lysis buffer (10% NP-40, 50mM Tris-HCl pH 7.5, and 100mM NaCl), 
and 200 μL of chloroform was added before drying in a vacuum concen-
trator. Lipids were extracted using 400 μL of chloroform and transferred to 
new tubes for drying. Lipids were reconstituted with 1 mL per 100 mg of 
tissue of a butanol mixture (6% butanol, 3.33% Triton-X100, and 0.66% 
methanol) and quantified using the Infinity Triglyceride Quantification Kit 
(Thermo Fisher Scientific, Waltham, Massachusetts).
Statistical analyses
All values are reported as mean (SEM). Statistical significance was de-
termined using unpaired two-tailed Student t test or one-way ANOVA 
for multiple groups using Fisher least significant difference test. All 
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gene expression data were  compared using two-way ANOVA with 
Dunnett multiple comparisons correction. All statistical analysis was 
performed using GraphPad Prism V6.05 (San Diego, California).
Results
HFD rechallenged mice have reduced eWAT mass 
and hyperinsulinemia compared with mice without 
prior HFD exposure
We used a dietary model of weight loss and regain in mice to assess the 
differences in metabolic and inflammatory measures between mice fed 
similar durations of HFD with and without preconditioning with weight 
loss (23). Male C57BL/6J mice were fed HFD or ND for 12 weeks. Obese 
mice were then maintained on HFD or switched to ND for 8 weeks to 
induce weight loss. Mice were then rechallenged with HFD for 6 weeks 
(RC-HFD). Age-matched control groups were mice fed ND for 20 weeks 
prior to the same 6-week short-term HFD challenge (ST-HFD) or mice 
continuously fed HFD long term for all 26 weeks (LT-HFD) (Figure 1A).
After weight loss, body weight in the RC-HFD group was  the same 
as age-matched mice fed ND (RC-HFD: 32.1 [1.5] g; ST-HFD: 30.4 
[1.1] g) (Figure 1B). After HFD rechallenge, RC-HFD mice weight was 
significantly higher (52.7 [1.5] g) than ST-HFD mice (43.9 [5.2]) fed 
for the same duration but was not significantly different from LT-HFD 
mice (52.0 [4.0] g) (Figure 1C). Compared with the ST-HFD group, 
total body energy expenditure was reduced in the RC-HFD mice and 
further reduced in the LT-HFD group (Figure 1D). One week after ini-
tiating HFD rechallenge, RC-HFD mice had higher food intake than 
ST-HFD and LT-HFD mice (Figure 1E). The reduced energy expendi-
ture and increased HFD intake likely explain the significantly elevated 
body weight of RC-HFD mice compared with ST-HFD mice.
GTT results were similar between RC-HFD and ST-HFD mice after 2 
and 4 weeks of HFD (Figure 1F-1G). ITT revealed comparable insulin 
sensitivity between ST-HFD and RC-HFD mice and impaired insulin 
tolerance in LT-HFD mice (Figure 1H). After 6 weeks of HFD feeding, 
fasting glucose was elevated in all three HFD groups compared with 
lean controls but did not differ between the HFD groups (Figure 1I). 
Serum insulin levels were significantly increased in RC-HFD mice com-
pared with ST-HFD mice (Figure 1J). Overall, these results suggest that 
formerly obese mice required elevated insulin levels to maintain similar 
glycemic control as mice that had not been previously exposed to HFD.
Markers of dysfunction in eWAT but not inguinal  
WAT of formerly obese mice after HFD rechallenge
Despite increased total body weight, eWAT in RC-HFD mice 
was significantly smaller than ST-HFD mice (Figure 2A). eWAT 
adipocyte size in ST-HFD, RC-HFD, and LT-HFD was not signifi-
cantly different (Figure 2B), suggesting impairments in adipocyte 
hyperplasia/adipogenesis in RC-HFD and LT-HFD groups. Histology 
demonstrated that ST-HFD mice had minimal CLS while RC-HFD 
and LT-HFD eWAT had high CLS content (Figure 2C). Immunoblots 
revealed reductions in proteins associated with mature differentiated 
adipocytes, including PPARγ, IRS-1, and AKT, in RC-HFD and LT-
HFD eWAT compared with ST-HFD eWAT (Figure 2D-2E). Gene 
expression showed reduced InsrI, Irs1, Cebpa, Pref1, and Glut4 ex-
pression in ST-HFD, LT-HFD, and RC-HFD eWAT compared with 
ND. Compared with ST-HFD mice, expression of these same genes 
as well as Cebpa, Pref1, and Glut4 was further reduced in RC-HFD 
and LT-HFD mice (Figure 2F).
To identify depot-specific effects, we evaluated inguinal subcutane-
ous WAT (iWAT). In contrast to eWAT, iWAT weight was increased in 
RC-HFD mice, compared with ST-HFD, and was similar to LT-HFD 
(Figure 2G). ST-HFD had similar ratios of iWAT to eWAT as ND and 
weight loss (WL) mice. In contrast, RC-HFD and LT-HFD had signifi-
cantly greater iWAT to eWAT ratios (Figure 2H), suggesting restricted 
lipid storage in eWAT with prior HFD exposure. No substantial dif-
ferences in iWAT CLS development were seen between diet groups 
(Figure 2I). Gene expression from iWAT revealed HFD-induced reduc-
tions in most mature adipocyte genes compared with ND, but no sig-
nificant differences between ST-HFD, RC-HFD, and LT-HFD groups 
were observed except for Lpl, which was increased in ST-HFD iWAT 
(Supporting Information Figure S1A). Inflammatory cytokine gene 
expression was also evaluated in iWAT, revealing no significant differ-
ences between groups (Supporting Information Figure S1B). Overall, in 
contrast to eWAT, iWAT expansion in RC-HFD mice was not impaired 
compared with ST-HFD mice but was associated with a lack of CLS 
development.
HFD rechallenge increases hepatic steatosis and 
markers of liver dysfunction
Liver weights were significantly elevated in RC-HFD mice compared 
with ST-HFD mice (Figure 3A-3B). Liver histology from ND and WL 
mice was similar, showing resolution of hepatic steatosis after 8 weeks 
off the HFD (Figure 3C). By histology, RC-HFD mice had signifi-
cantly elevated hepatic steatosis compared with ST-HFD and similar to 
LT-HFD mice (Figure 3C-3D). Total hepatic triglyceride content was more 
than twofold higher in RC-HFD and LT-HFD mice when compared 
with ST-HFD (Figure 3E-3F). Serum triglyceride concentrations were 
similar between groups (Figure 3G). Serum aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels were quantified as 
markers of hepatocyte stress and damage. RC-HFD mice had signifi-
cantly elevated AST and ALT compared with ST-HFD mice that were 
similar to the LT-HFD group (Figure 3H). Overall, this demonstrates 
Figure 2 HFD rechallenge increases epididymal adipose tissue CLS and reduces expression of proteins 
essential for mature adipocyte development and function. (A) Total epididymal WAT (eWAT) weight and 
as a percent of total body weight (n = 4). (B) eWAT adipocyte size distribution (n = 3 for RC-HFD and n = 4 
for other diet conditions). (C) Immunofluorescence and hematoxylin and eosin (H&E) stained eWAT slides 
representative for each diet condition showing CLS development and maintenance. (D) Representative 
immunoblots from eWAT showing select adipocyte maturation and insulin signaling proteins. (E) 
Quantification of densitometry measurements from immunoblots of whole eWAT (n = 3). (F) Expression of 
adipocyte maturation genes from eWAT (n = 4). (G) Inguinal WAT (iWAT) total weight and as percent of total 
body weight (n = 4). (H) Ratio of iWAT to eWAT after HFD rechallenge (n = 4). (I) H&E stained iWAT slides 
representative for each diet condition. Two-way ANOVA with Dunnett multiple comparisons for F. *P < 0.05, 
**P < 0.01, ****P < 0.0001; significance was compared only  for ST-HFD versus RC-HFD, LT-HFD versus 
RC-HFD, or ND versus WL. [Color figure can be viewed at wileyonlinelibrary.com]
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that prior HFD exposure potentiates hepatocellular dysfunction and ste-
atosis upon repeat challenge to HFD.
To determine whether the increased hepatic triglyceride content was 
due to increased hepatic lipogenesis, we evaluated several hepatic lipid 
and glucose metabolism genes. Compared with ST-HFD and RC-HFD 
mice, LT-HFD induced Lpl and Pparg expression but showed no sig-
nificant differences in expression of Scd1, Srebp1, Fasn, Me1, Acaca, 
Fabp1, G6pc, Pck1, or Gck. No differences in expression of genes 
involved in lipid metabolism were seen between RC-HFD and ST-HFD 
Figure 3 Increased liver steatosis and signs of liver damage with HFD rechallenge. (A) Representative H&E stained slides from livers 
showing steatosis development and (B) percent of surface area with lipid involvement from H&E images (n ≥ 4). (C) Liver weight and 
(D) liver as a percent of total body weight (n = 4). (E) Liver triglyceride concentration and (F) total liver triglyceride content (n = 4). Serum 
concentrations for (G) triglycerides (n ≥ 4), (H) aspartate aminotransferase (AST, left; n = 4), and alanine aminotransferase (ALT, right; 
n = 4). *P < 0.05, **P < 0.01, ****P < 0.0001; significance was only compared for ST-HFD versus RC-HFD, LT-HFD versus RC-HFD, or 
ND versus WL. [Color figure can be viewed at wileyonlinelibrary.com]
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Figure 4 HFD rechallenge after 24 weeks of weight loss reveals prolonged defects in epididymal WAT (eWAT) expansion 
capacity. (A) Cartoon showing extended ND-switch period of 24 weeks followed by 6 weeks of HFD rechallenge. (B) Body 
weight of mice after 24 weeks of ND-switch and then rechallenging with HFD. (C) eWAT weight and (D) inguinal WAT (iWAT) 
weight after HFD rechallenge. (E) Representative immunofluorescence images showing CLS retention. (F) Fasting blood 
glucose after HFD challenge. (G) Representative liver hematoxylin and eosin (H&E) slides showing steatosis development. 
(H) Liver weight and (I) total liver triglyceride content after HFD rechallenge. For panels B-D, F, H, and I, n = 4. *P < 0.05, 
**P < 0.01, ***P < 0.001; significance was compared only  for Ex-ST-HFD versus Ex-RC-HFD or Ex-LT-HFD versus Ex-RC-
HFD. [Color figure can be viewed at wileyonlinelibrary.com]
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livers (Supporting Information Figure S2A-S2B). These results sug-
gest that the increased hepatic triglyceride storage was not the result of 
increased de novo lipogenesis in liver. Liver inflammatory gene expres-
sion revealed significantly increased expression of Tnfa in RC-HFD 
and LT-HFD mice compared with ST-HFD but no differences in Il1b 
and Il6 expression (Supporting Information Figure S2C). Leukocyte 
gene expression for F480 and Cd3 was elevated in LT-HFD mice but 
was not significantly different between ST-HFD and RC-HFD mice 
(Supporting Information Figure S2D).
HFD rechallenge effects are retained despite 
extended weight loss
To evaluate the durability of the effects of prior obesity, we extended the 
duration of weight loss to 24 weeks and then rechallenged mice with 
HFD for 6 weeks (Ex-RC-HFD) (Figure 4A). Age-matched control mice 
were maintained on extended ND (Ex-ST-HFD) and extended HFD 
(Ex-LT-HFD). The Ex-RC-HFD group weighed significantly more than 
age-matched Ex-ST-HFD mice and significantly less than Ex-LT-HFD 
mice (Figure 4B). eWAT was reduced in Ex-RC-HFD and Ex-LT-HFD 
mice compared with Ex-ST-HFD mice in both total mass and as a 
percent of body weight (Figure 4C). iWAT weight was not significantly 
different between Ex-RC-HFD and Ex-ST-HFD mice, but both were less 
than Ex-LT-HFD (Figure 4D). Immunofluorescence of eWAT revealed 
increased CLS in Ex-RC-HFD and Ex-LT-HFD mice compared with 
Ex-ST-HFD mice (Figure 4E). Gene expression for adipocyte matura-
tion in eWAT revealed no significant differences between diet conditions 
(Supporting Information Figure S3A). Fasting blood glucose of Ex-RC-
HFD mice was significantly elevated compared with Ex-LT-HFD mice 
but not when compared with Ex-ST-HFD mice (Figure 4F).
Liver histology revealed substantial steatosis in all three diet conditions 
(Figure 4G). Total and percent liver weight was significantly elevated 
in Ex-RC-HFD and Ex-LT-HFD mice compared with Ex-ST-HFD 
(Figure 4H). Liver triglycerides were increased in the Ex-RC-HFD 
and Ex-LT-HFD mice compared with Ex-ST-HFD mice (Figure 4I). 
Liver gene expression revealed no significant differences between 
groups for lipid and glucose metabolism genes assessed (Supporting 
Information Figure S3B-S3C). Overall, the results show that increas-
ing the recovery time off HFD from 8 to 24 weeks did not improve 
eWAT expansion or diminish the development of hepatic steatosis with 
HFD rechallenge.
Figure 5 Increased CD11c+ adipose tissue macrophage (ATM) accumulation and inflammation with HFD rechallenge. (A) Frequency of CD45+ 
leukocytes of all epididymal WAT (eWAT) SVF. (B) Total ATM content per eWAT pad and (C) frequency of all CD45+CD64+ ATMs that express 
CD11c. (D) Total T-cell content per eWAT pad. Frequency of (E) CD4+ and (F) CD8+ cells of all adipose tissue T cells. (G) Expression of select 
inflammatory cytokine genes from whole eWAT. For panels A-F, n = 4; for panel G, n = 3 for ND and WL diet conditions and n = 4 for ST-HFD, 
RC-HFD, and LT-HFD conditions. *P < 0.05, **P < 0.01, ***P < 0.001; significance was compared only  for ST-HFD versus RC-HFD, LT-HFD 
versus RC-HFD, or ND versus WL.
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eWAT leukocyte content is increased after HFD 
rechallenge
Adipose tissue leukocyte composition was analyzed to determine the 
impact of HFD rechallenge on eWAT stromal content. Flow cytometry 
revealed increased total leukocyte accumulation in the eWAT SVF of 
RC-HFD compared with ST-HFD but less than what was observed in 
LT-HFD mice (Figure 5A). The total number of eWAT adipose tissue 
macrophages (ATM) was also significantly increased in RC-HFD mice 
as well as the frequency of CD11c+ ATMs (Figure 5B-5C). Analysis of 
adipose tissue T-cell populations showed a trend toward an increase in 
total T-cell content in RC-HFD mice. However, there was a significantly 
higher frequency of CD8+ T cells in RC-HFD mice compared with 
ST-HFD mice (Figure 5D-5F). eWAT inflammatory cytokine expres-
sion showed Tnfα was increased in RC-HFD and LT-HFD mice com-
pared with ST-HFD, but Il1β and Il6 expression did not differ between 
groups (Figure 5G). Overall, HFD rechallenge promoted increased in-
flammation and accelerated accumulation of leukocytes within eWAT.
Obesity imposes durable increase in eWAT 
preadipocytes despite weight loss
Our observations of decreased eWAT expansion and similar adipocyte 
size in RC-HFD compared with ST-HFD mice suggest that adipogen-
esis may be impaired in formerly obese mice. We quantified adipose 
tissue preadipocytes in the flow cytometry defined as CD45−CD31−Sca-
1+PDGFrα+ cells (28,29). After weight loss, eWAT had an increase in 
preadipocytes compared with lean mice that was comparable to HFD 
mice (Figure 6A). This increase in preadipocytes was not observed in 
iWAT (Figure 6B). Because the increase in preadipocytes correlated 
with adipose tissue fibrosis during weight loss (23), we used intracel-
lular flow cytometry to quantify collagen I+ (Col1+) preadipocytes in 
lean, obese, and WL groups (Figure 6C-6D). This demonstrated an in-
crease in Col1+ preadipocytes in WL and HFD-fed mice in eWAT. Col1+ 
preadipocytes were induced by obesity in iWAT but were reduced after 
weight loss. This suggests that eWAT of formerly obese mice contained 
an expanded preadipocyte pool that expressed profibrotic markers and 
correlated with an inability to properly expand during HFD rechallenge.
eWAT of formerly obese mice secretes factors 
that inhibit adipogenesis
To examine the mechanism of this failure of adipose tissue to expand 
after HFD rechallenge, we utilized an in vitro model. CM was collected 
from eWAT explant cultures from ND and WL mice in serum-free 
media for 24 hours and added to 3T3-L1 during induction of adipogen-
esis. CM from WL mice significantly increased genes normally associ-
ated with preadipocyte cells, rather than mature adipocytes, including 
Pref1, Col1a1, Col3a1, Acta2, and Fn1 expression compared with ND 
CM treatment (Figure 7A-7B). Oil Red O staining showed that both 
WL and HFD CM treatment significantly reduced lipid storage com-
pared with ND CM treatment (Figure 7C-7D).
To determine what factors might be responsible for inhibiting adipogen-
esis, cytokine arrays evaluated eWAT explant CM from ND, WL, and 
HFD mice after 48 hours in culture. We observed that IL1ra and chemo-
kines CCL4, CXCL9, CCL5, and CCL12 were elevated in WL CM 
compared with ND CM (Figure 7E). Treatment of 3T3-L1 cells during 
differentiation with these chemokines revealed a small, but significant, 
reduction in differentiation assessed by Oil Red O (Figure 7F). While 
Figure 6  Epididymal  WAT (eWAT)  of formerly obese mice maintains elevated numbers of 
preadipocytes. CD45−CD31−Sca-1+PDGFRα+ preadipocytes in ND, WL, and HFD mice 
were quantified by flow cytometry in (A) eWAT (n = 4 for all conditions) and (B) inguinal WAT 
(iWAT) (n = 4 for ND and n = 3 for WL and HFD). Quantity of collagen I (Col1+) preadipocytes 
was determined by intracellular flow cytometry in (C) eWAT (n = 4 for all conditions) and 
(D) iWAT (n = 4 for ND and n = 3 for WL and HFD). *P < 0.05, ***P < 0.001; significance was 
compared only for ND versus WL or WL versus HFD (20 weeks).
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treatment with single chemokines only minimally inhibited differentia-
tion, treatment with all four simultaneously abolished inhibition.
TNFα is a known potent inhibitor of adipogenesis (30). Because 
gene expression for Tnfα was elevated in WL, RC-HFD, and 
LT-HFD eWAT (Figure 5G), we sought to determine if TNFα might 
play a role in inhibiting adipogenesis in our culture model. TNFα-
neutralizing antibody was added to CM from eWAT explants before 
treating 3T3-L1 cells. Treatment of differentiating 3T3-L1 cells with 
ST-HFD, RC-HFD, or LT-HFD CM resulted in equivalent inhibition 
Figure 7  CM from epididymal WAT (eWAT) explants of formerly obese mice inhibits adipocyte differentiation and reduces 
lipogenesis. Gene expression for (A) adipocyte maturation genes and (B) collagen genes after differentiation induction in the 
presence of eWAT explant CM from the respective diet conditions (n = 4). Oil Red O staining of lipid droplets within differentiated 
adipocytes shown as (C) representative micrographs and (D) relative total extracted Oil Red O content from wells (n = 3). (E) 
eWAT explant multiplex cytokine array (n = 1 for ND and n = 2 for WL and HFD). (F) Extracted relative Oil Red O content from 
differentiated 3T3-L1 cells after treatment with (left) 10 ng/mL of individual chemokines identified from multiplex cytokine 
array or (right) simultaneous treatment with all identified chemokines at 10 ng/mL each (n ≥ 3). (G) Extracted relative Oil Red O 
absorbance after treatment with CM from ST-HFD, RC-HFD, or LT-HFD with or without the addition of 50 ng/mL of neutralizing 
anti-TNFα antibody (αTNF) during differentiation (n ≥ 4). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; significance was 
compared only  for ST-HFD versus RC-HFD, LT-HFD versus RC-HFD, or ND versus WL unless otherwise noted. Undiff., 
undifferentiated control; Diff., differentiated control, All Chemok., all identified chemokines. [Color figure can be viewed at 
wileyonlinelibrary.com]
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of differentiation and was similar to what was observed after WL CM 
or HFD CM treatment (Figure 7G). Exposure to TNFα-neutralizing 
antibody caused small but significant improvement when added to 
ST-HFD eWAT CM, but no differences were seen in the RC and 
LT-HFD CM. Overall, the results show that eWAT of obese and 
formerly obese mice secrete multiple factors that may contribute to 
impaired adipogenesis and the failure to induce new adipocyte for-
mation upon HFD rechallenge.
Discussion
We have previously demonstrated that eWAT of formerly obese mice 
maintains activated leukocytes’ abnormal eWAT structure (23). In this 
study, we assess the metabolic and inflammatory consequences of re-
challenging formerly obese mice with HFD. Our major finding was that 
basic functions of adipose tissue to respond to HFD were permanently 
impaired in formerly obese mice. eWAT of formerly obese mice was 
unable to efficiently store excessive nutrients and led to increased ec-
topic lipid storage in the liver and iWAT upon HFD rechallenge. This 
derangement persists despite extended time off HFD and suggests a 
permanent impact of obesity on eWAT function and architecture. 
Compared with weight-matched mice not previously exposed to HFD, 
RC-HFD mice had exaggerated induction of ATMs, increased CD8+ 
tissue T cells, and increased inflammatory cytokine expression. HFD 
challenge of formerly obese mice led to reduced eWAT mass with iden-
tical adipocyte size compared with ST-HFD mice, suggesting impaired 
adipocyte hyperplasia. The mechanism behind these findings relates to 
an increased number of ColI+ preadipocytes as well as eWAT secreted 
chemokines that can inhibit in vitro adipogenesis.
Our observations are similar to other weight-cycling models in rodents 
that suggest deleterious effects of repeat exposure to HFD (16-18). Our 
longer initial HFD exposure (12 weeks) is designed to examine the 
impact of a prolonged obese state. We note that the RC-HFD group 
is exposed to HFD for a longer total time than the ST-HFD group, 
which may contribute to the differences between groups. Our results 
are consistent with studies showing that obesity duration is associated 
with diabetes in women (31). Our study is unique, as we assessed the 
durability of the alterations induced by HFD exposure and show that 
prolonged recovery did not “normalize” the adipose tissue environment 
or its lipid storage capacity. Observations of maintained inflammation 
and insulin resistance are seen in both mice and humans after weight 
loss (20-21,24-26,32) and is consistent with the genetic evidence that 
limited peripheral nutrient storage in adipose tissue contributes to dia-
betes (33).
The limited capacity for eWAT expansion was observed despite a 
quantitative increase in preadipocytes in formerly obese mice, sug-
gesting that they may have impaired differentiation capacity. This 
relates to an increase in Col1+ preadipocytes, suggesting that they are 
assuming a myofibroblast phenotype with impaired differentiation 
(34). In support of this concept, we observed that expression of sev-
eral critical mature adipocyte-specific genes and proteins were signifi-
cantly decreased in formerly obese eWAT and remained lower after 
HFD rechallenge. TNFα neutralization experiments suggested that 
TNFα may play little, if any, role toward inhibiting adipogenesis in 
the weight loss context. Other adipogenesis inhibitors exist that have 
yet to be examined in our system, including, but not limited to, IL-6 
(35), Wnt-5a (36), IL-1β (37,38), macrophage inhibitory factor, and 
even fatty acids such as arachidonic acid (39). Future work is needed 
to clarify if adipose dysfunction in weight loss is due to factors inhib-
iting adipogenesis versus permanent defects in adipocyte maturation 
after obesity.
Relative to the ST-HFD group, RC-HFD mice had elevated total and 
CD11c+ ATMs as well as an increase in CD8+ adipose tissue T cells. 
These features resembled the leukocyte increases seen in mice after 
weight loss and are further evidence of persistence of adipose tissue 
inflammatory leukocytes once they are established with chronic HFD 
exposure. This observation is consistent with recent single-cell RNA 
sequencing studies that have shown that caloric restriction with an HFD 
sustains a phagocytic ATM population and that gene expression path-
ways related to inflammation largely resemble obese as opposed to lean 
mice (40). We have previously shown that macrophage proliferation is 
a component of this mechanism of this retention; however, new macro-
phage recruitment or turnover cannot be ruled out (23).
The livers from RC-HFD mice revealed disproportionally increased 
liver mass with substantially increased steatosis and total triglyceride 
content compared with the ST-HFD group. The association between 
adipocyte death and CLS with increased ectopic deposition of lipids 
into the liver is consistent with other observations (41). In RC-HFD 
mice, nutrient storage into eWAT was impaired and shifted into iWAT 
depots; however, this was not sufficient to prevent lipid deposition in 
the liver, suggesting specific roles for eWAT in preventing steatosis in 
mice. Steatosis was associated with increased serum concentrations 
of AST and ALT, indicating liver damage. The ALT to AST ratio was 
greater than 2:1 in both RC-HFD and LT-HFD mice compared with 
1.3:1 in ST-HFD mice. This ratio matches a classical change observed 
in patients with early stage nonalcoholic fatty liver disease and is asso-
ciated with obesity and increased risk for type 2 diabetes (42). ST-HFD 
and RC-HFD mice had similar glucose tolerance with substantially 
increased liver steatosis. However, fasting insulin levels were almost 
twofold higher in RC-HFD and LT-HFD mice, indicating increased 
insulin resistance in the RC-HFD mice, consistent with previous find-
ings showing accrued liver steatosis and impaired liver insulin signaling 
in weight-cycling models (18,43).
Overall, we were able to identify unique physiological differences 
associated with weight regain in formerly obese mice. These findings 
indicate that obesity may result in long-term impairments in adipose 
tissue function. Future work is needed to investigate the physiological 
consequences of obesity that remain despite weight loss as well as the 
mechanisms that limit long-term adipocyte function hypertrophy and 
hyperplasia.O
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